R717 (Lamotrigine extended-release 25 mg)
Pill imprint R717 has been identified as Lamotrigine extended-release 25 mg.
Lamotrigine is used in the treatment of bipolar disorder; schizoaffective disorder; borderline personality disorder; anxiety; seizure prevention (and more), and belongs to the drug class triazine anticonvulsants. Risk cannot be ruled out during pregnancy. Lamotrigine 25 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- R717
- Strength:
- 25 mg
- Color:
- Yellow
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Triazine anticonvulsants
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Dr.Reddy's Laboratories Limited
More about lamotrigine
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 731 Reviews – Add your own review/rating
- Drug class: triazine anticonvulsants
Consumer resources
- Lamotrigine
- Lamotrigine chewable dispersible tablets
- Lamotrigine extended-release tablets
- Lamotrigine orally disintegrating tablets
- Lamotrigine (Advanced Reading)
Other brands: Lamictal, Lamictal XR, Lamictal ODT, Lamictal CD
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
